Journal article
Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics
Abstract
BACKGROUND: Psoriasis in clinical trials is often measured by the Psoriasis Area and Severity Index (PASI). This measurement is well understood by clinical trialists and many dermatologists but rarely by patients and some clinicians. Patients may not understand their chance of improvement based on a PASI-50 or PASI-75 value (50 or 75% improvement in PASI score). They would better understand a PASI average presented as the mean percent …
Authors
English PL; Vender R
Journal
Journal of Cutaneous Medicine and Surgery, Vol. 12, No. 6, pp. 282–287
Publisher
SAGE Publications
Publication Date
November 2008
DOI
10.2310/7750.2008.07079
ISSN
1203-4754
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdalimumabAlefaceptAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedClinical Trials, Phase III as TopicDermatologic AgentsEtanerceptHumansImmunoglobulin GInfliximabInfusions, IntravenousInjections, IntramuscularInjections, SubcutaneousMulticenter Studies as TopicPsoriasisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis FactorRecombinant Fusion ProteinsSeverity of Illness IndexTime FactorsTreatment Outcome